Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy

BACKGROUND: Cancer immunotherapy has evolved from interferon-alpha (IFNα) and interleukin-2 in the 1980s to CTLA-4 and PD-1/PD-L1 checkpoint inhibitors (CPIs), the latter highlighting the importance of enhancing T-cell functions. While the search for novel immunomodulatory pathways continues, combin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Cubas, Rafael, Khan, Zia, Gong, Qian, Moskalenko, Marina, Xiong, Huizhong, Ou, Qinglin, Pai, Christine, Rodriguez, Ryan, Cheung, Jeanne, Chan, Andrew C
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Basic Tumor Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604869/
https://ncbi.nlm.nih.gov/pubmed/33127657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001439
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars